Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kyverna Therapeutics, Inc. - Common Stock
(NQ:
KYTX
)
4.890
+0.110 (+2.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kyverna Therapeutics, Inc. - Common Stock
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
September 25, 2024
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.
Via
Investor's Business Daily
Toll Brothers Posts Strong Earnings, Joins Keysight, Coty, TJX And Other Big Stocks Moving Higher On Wednesday
August 21, 2024
Via
Benzinga
Home Depot, Paysafe And 3 Stocks To Watch Heading Into Tuesday
August 13, 2024
Via
Benzinga
KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q2 2024
August 12, 2024
KYTX stock results show that Kyverna Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
July 19, 2024
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune...
Via
Benzinga
Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday
July 16, 2024
Via
Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 14, 2024
Via
Benzinga
KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
June 14, 2024
From
The Schall Law Firm
Via
Business Wire
Why Kyverna Therapeutics Stock Is Sinking
June 14, 2024
Kyverna Therapeutics shares are falling Friday. The company released a presentation on KYV-101, its CD19 CAR T-cell candidate. Here's a look at the details:
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 14, 2024
Via
Benzinga
Dow Tumbles Over 200 Points; Adobe Earnings Top Views
June 14, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 13, 2024
Via
Benzinga
Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday
June 13, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 03, 2024
Via
Benzinga
KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024
May 14, 2024
KYTX stock results show that Kyverna Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
April 01, 2024
Via
Benzinga
Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
February 25, 2024
The market's excited for these stocks, but there's no rush to buy them.
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Securities Market
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
February 11, 2024
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.